Successful Vaccination of Patients with History of Severe Anaphylactic Reaction with Pfizer-Biotech COVID-19 Vaccine

Authors

  • Humaid O. Al-Shamsi Department of Medical Oncology – Burjeel Cancer Institute – Burjeel Medical City, Abu Dhabi, United Arab Emirates Author
  • Muzna Alzaabi Royal College of Surgeons in Ireland, Dublin, Republic of Ireland Author
  • Eric A Coomes University of Toronto, Toronto, Ontario, Canada Author

DOI:

https://doi.org/10.47363/JONRR/2021(2)124

Keywords:

Anaphylactic, COVID-19 Vaccine, Pfizer-Biotech

Abstract

A history of severe anaphylactic reaction to a vaccine components is a contraindication for all currently approved COVID-19 vaccinations [1,2]. We report a successful vaccination of two patients with a history of severe anaphylactic reaction with PfizerBioNTech COVID-19 Vaccine. During December 14 to 23, 2020, after administration of a reported 1 893 360 first doses of PfizerBioNTech COVID-19 vaccine, CDC identified 21 case reports, corresponding to an estimated rate of 11.1 cases per million doses administered. No deaths from anaphylaxis were reported [3].

Author Biographies

  • Humaid O. Al-Shamsi, Department of Medical Oncology – Burjeel Cancer Institute – Burjeel Medical City, Abu Dhabi, United Arab Emirates

    Department of Medical Oncology – Burjeel Cancer Institute – Burjeel Medical City, Abu Dhabi, United Arab Emirates

  • Muzna Alzaabi, Royal College of Surgeons in Ireland, Dublin, Republic of Ireland

    Royal College of Surgeons in Ireland, Dublin, Republic of Ireland

  • Eric A Coomes, University of Toronto, Toronto, Ontario, Canada


    University of Toronto, Toronto, Ontario, Canada

Downloads

Published

2021-03-19

Issue

Vol. 2 No. 2 (2021): Volume 2 Issue 2

Section

Articles